Business Context and Reporting Period
This Form 8-K is a current report filed by Inotek Pharmaceuticals Corporation (not Rocket Pharmaceuticals, Inc.) on August 17, 2016. The filing reports the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the election of Patrick Machado as a new Class III director on August 17, 2016. The Board determined Mr. Machado satisfies the definition of an "independent" director under NASDAQ Listing Rules and the Securities Exchange Act of 1934. He was also appointed to the Audit Committee.
Guidance, Outlook, and Compensation
- Compensation: Upon election, Mr. Machado was granted an option to purchase 24,000 shares of common stock at an exercise price of $6.91 per share (fair market value on the grant date).
- Vesting Schedule: 25% of the shares vest on the one-year anniversary of the grant date; the remaining shares vest monthly (1/36th) thereafter, subject to continued service.
- Other Arrangements: Mr. Machado will receive standard non-employee director compensation and entered into a standard indemnification agreement. No related person transactions or family relationships with other directors were disclosed.
- Outlook: The filing contains no financial guidance or management commentary regarding business outlook.
Investor Verification Checklist
- Verify the correct registrant name is Inotek Pharmaceuticals Corporation, not Rocket Pharmaceuticals, Inc.
- Confirm the stock price of $6.91 on August 17, 2016, to validate the option exercise price.
- Review the press release (Exhibit 99.1) for additional context on the appointment.
- Check subsequent filings for the impact of this appointment on the Audit Committee composition.